Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery

Analytical Biochemistry

Volumn 356, Issue 2, 2006, Pages 273-281

  Jia, Yong ^a   Quinn, Christopher M ^a   Gagnon, Andrew I ^a   Talanian, Robert ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

HTRF; Inhibitor; Kinase assay; Kinetics; Mechanism

Indexed keywords

DRUG PRODUCTS; ENERGY TRANSFER; ENZYME KINETICS; FLUORESCENCE; KINETICS; MECHANISMS;

DISSOCIATION KINETICS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HTRF; INHIBITOR; KINASE ASSAYS; THERAPEUTIC INTERVENTION; TIME-RESOLVED FLUORESCENCE;

ENZYMES;

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE; DORAMAPIMOD; PHOSPHOTRANSFERASE;

ARTICLE; BINDING KINETICS; CHEMICAL PROCEDURES; CHEMICAL REACTION; DISSOCIATION; DRUG BINDING; ENZYME ASSAY; ENZYME KINETICS; FLUORESCENCE; PRIORITY JOURNAL;

EID: 33747880633     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2006.05.006     Document Type: Article

References (32)

1. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
2. Hunter T. Signaling-2000 and beyond. Cell 100 (2000) 113-127
3. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
4. Cohen P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 3 (1999) 459-465
5. Cohen P. Protein kinases-the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
6. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc. Chem. Res. 36 (2003) 462-469
7. Force T., Kuida K., Namchuk M., Parang K., and Kyriakis J.M. Inhibitors of protein kinases signaling pathways: emerging therapies for cardiovascular disease. Circulation 109 (2004) 1196-1205
8. Mazitschek R., and Giannis A. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. Curr. Opin. Chem. Biol. 8 (2004) 432-441
9. Resnick L., and Fennell M. Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discov. Today 9 (2004) 932-939
10. Cohen P., and Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 3 (2004) 479-487
11. Fabbro D., and Garcia-Echeverria C. Targeting protein kinases in cancer therapy. Curr. Opin. Drug Discov. Dev. 5 (2002) 701-712
12. Myers M.R., He W., and Hulme C. Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr. Pharm. Des. 3 (1997) 473-502
13. Mathis G. HTRF technology. J. Biomol. Screen. 4 (1999) 309-313
14. Mathis G. Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin. Chem. 41 (1995) 1391-1397
15. Hemmilä I. LANCE: homogeneous assay platform for HTS. J. Biomol. Screen. 4 (1999) 303-307
16. Greg W., Chantal I., Liliana P., Philippe R., and Roger B. AlphaScreen kinase HTS platforms. Curr. Med. Chem. 11 (2004) 721-730
17. Sadler T.M., Achilleos M., Ragunathan S., Pitkin A., LaRocque J., Morin J., Annable R., Greenberger L.M., Frost P., and Zhang Y. Development and comparison of two nonradioactive kinase assays for I kappa B kinase. Anal. Biochem. 326 (2004) 106-113
18. Seethala R., and Menzel R. A fluorescence polarization competition immunoassay for tyrosine kinases. Anal. Biochem. 255 (1998) 257-262
19. Gaudet E.A., Huang K.-S., Zhang Y., Huang W., Mark D., and Sportsman J.R. A homogeneous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. J. Biomol. Screen. 8 (2003) 164-175
20. Morgan A.G., McCauley T.J., Stanaitis M.L., Mathrubutham M., and Millis S.Z. Development and validation of a fluorescence technology for both primary and secondary screening of kinases that facilitates compound selectivity and site-specific inhibitor determination. Assay Drug Dev. Technol. 2 (2004) 171-181
21. Xia W., Rininsland F., Wittenburg S.K., Shi X., Achyuthan K.E., McBranch D.W., and Whitten D.G. Application of fluorescent polymer superquenching to high throughput screening assays for protein kinases. Assay Drug Dev. Technol. 2 (2004) 183-192
22. Rodems S.M., Hamman B.D., Lin C., Zhao J., Shah S., Heidary D., Makings L., Stack J.H., and Pollok B.A. A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev. Technol. 1 (2002) 9-19
23. Cohen C.B., Chin-Dixon E., Jeong S., and Nikiforov T.T. A microchip-based enzyme assay for protein kinase A. Anal. Biochem. 273 (1999) 89-97
24. Koresawa M., and Okabe T. High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. Assay Drug Dev. Technol. 2 (2004) 153-160
25. Shults M.D., and Imperiali B. Versatile fluorescence probes of protein kinase activity. J. Am. Chem. Soc. 125 (2003) 14248-14249
26. Shults M.D., Janes K.A., Lauffenburger D.A., and Imperiali B. A multiplexed homogeneous fluorescence-based assay for protein kinase activity in cell lysates. Nat. Methods 2 (2005) 277-284
27. Luo Y., Shoemaker A.R., Liu X., Woods K.W., Thomas S.A., de Jong R., Han E.K., Li T., Stoll V.S., Powlas J.A., Oleksijew A., Mitten M.J., Shi Y., Guan R., McGonigal T.P., Klinghofer V., Johnson E.F., Leverson J.D., Bouska J.J., Mamo M., Smith R.A., Gramling-Evans E.E., Zinker B.A., Mika A.K., Nguyen P.T., Oltersdorf T., Rosenberg S.H., Li Q., and Giranda V.L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 4 (2005) 977-986
28. Regan J., Breitfelder S., Cirillo P., Gilmore T., Graham A.G., Hickey E., Klaus B., Madwed J., Moriak M., Moss N., Pargellis C., Pav S., Proto A., Swinamer A., Tong L., and Torcellini C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 45 (2002) 2994-3008
29. Jia Y., Quinn C.M., Clabbers A., Talanian R., Xu Y., Wishart N., and Allen H. Comparative analysis of various in vitro COT kinase assay formats and their applications in inhibitor identification and characterization. Anal. Biochem. 350 (2006) 268-276
30. Mathis G. Rare earth cryptate and homogeneous fluoroimmunoassays with human sera. Clin. Chem. 39 (1993) 1953-1959
31. Young P.R., McLaughlin M.M., Kumar S., Kassis S., Doyle M.L., McNulty D., Gallagher T.F., Fisher S., McDonnell P.C., Carr S.A., Huddleston M.J., Seibel G., Porter T.G., Livi G.P., Adams J.L., and Lee J.C. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 272 (1997) 12116-12121
32. Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., and Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9 (2002) 268-272